Cancer researcher and break-through drug developer Geoffrey Weiss recently was appointed the University Medical Center's newest chief of hematology-oncology and deputy director of the cancer center.
Weiss previously conducted research at the University of Texas, where he developed the cancer fighting drug interleukin-2, which was approved by the Food and Drug Administration in 1993.
Interleukin-2, used primarily to combat kidney and skin cancer, results in remission among 20 percent of the patients who use it.
Weiss told the Daily Progress that in his new role at the University, he plans to develop targeted therapies, drugs that work to destroy altered cancer-causing cell proteins.
Weiss said he also plans to hire nine new researchers within the next five years and earn the University's Medical Center a top-10 ranking for cancer research.
Read More
How does U.Va.’s agreement with the Justice Department compare to the Compact?
By Nicolas Biernacki | 18 hours agoWhile both the rejected Compact and the Justice Department agreement faced resistance from the University community and have several similarities, the agreement provides firmer protection for academic freedom.
New residential college policy prioritizes rising second-years in rehousing assignments
By Brandon Kile | 19 hours agoA new on-Grounds housing policy concerning residential colleges will change the reapplication system to give rising second years who are returning to the colleges priority in the housing process.
Paul Cherukuri leads U.Va.’s entrepreneurship strategy as its first chief innovation officer
By Bertie Azqueta | YesterdayPaul Cherukuri was recently named the University’s first chief innovation officer in August, a role within the Office of the Vice President for Research that was created to help expand student entrepreneurship and start-up activity at the University.
